Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR OCTREOTIDE ACETATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Octreotide Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002779 ↗ Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 1998-02-01 RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin's lymphoma.
NCT00002779 ↗ Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Completed Alliance for Clinical Trials in Oncology Phase 2 1998-02-01 RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin's lymphoma.
NCT00002864 ↗ Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCIC Clinical Trials Group Phase 3 1996-09-24 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of estrogen. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without octreotide in treating postmenopausal women who have stage I, stage II, or stage III breast cancer.
NCT00003057 ↗ Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed Cancer and Leukemia Group B Phase 3 1996-11-01 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 ↗ Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed National Cancer Institute (NCI) Phase 3 1996-11-01 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 ↗ Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed Southwest Oncology Group Phase 3 1996-11-01 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Octreotide Acetate

Condition Name

Condition Name for Octreotide Acetate
Intervention Trials
Acromegaly 12
Colorectal Cancer 5
Diarrhea 5
Diabetic Retinopathy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Octreotide Acetate
Intervention Trials
Acromegaly 12
Neuroendocrine Tumors 10
Carcinoid Tumor 8
Diarrhea 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Octreotide Acetate

Trials by Country

Trials by Country for Octreotide Acetate
Location Trials
United States 216
Canada 14
Italy 4
Romania 3
Ukraine 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Octreotide Acetate
Location Trials
Ohio 9
Minnesota 9
Illinois 9
Iowa 8
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Octreotide Acetate

Clinical Trial Phase

Clinical Trial Phase for Octreotide Acetate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 16
Phase 2 14
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Octreotide Acetate
Clinical Trial Phase Trials
Completed 27
Terminated 8
Not yet recruiting 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Octreotide Acetate

Sponsor Name

Sponsor Name for Octreotide Acetate
Sponsor Trials
National Cancer Institute (NCI) 17
Novartis Pharmaceuticals 7
Eastern Cooperative Oncology Group 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Octreotide Acetate
Sponsor Trials
Industry 23
Other 23
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKinsey
Johnson and Johnson
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.